Search results
New Horizons in Obesity Management 2026
Start date:
Jun 17, 2026
Broadcast
Added:
1 year ago
THT Conference 2025 - Outcomes assessing the effect of obesity severity on tirzepatide in patients with obesity-related heart failure with preserved ejection fraction (HFpEF) show that patients on tirzepatide with a greater reduction in BMI and baseline waist-to-height ratio had greater improvements in exercise capacity and KCCQ quality of life scores.Dr Barry Borlaug (Mayo Clinic and Foundation,…
View more
Added:
11 months ago
ESC HF 25 - Safety outcomes from PRAISE-HFrEF show that glucagon-like peptide-1 receptor agonism (GLP-1 RA) treatment for heart failure with reduced ejection fraction (HFrEF) and obesity was not associated with increased risk of heart failure hospitalisation or mortality compared to placebo, with greater benefits observed in patients with higher BMI.Dr Varun Sundaram (Case Western Reserve…
View more
Added:
1 year ago
AHA Conference 2024 — New insights into the SUMMIT trial, investigating tirzepatide in patients with heart failure with preserved ejection fraction (HFpEF) and obesity.Dr Harriette Van Spall (McMaster University, CA) is joined by Dr Milton Packer (Baylor Heart and Vascular Institute, US) to discuss the findings from the randomized, double-blind, phase 3 SUMMIT trial (NCT04847557) investigating…
View more
Added:
2 months ago
Source:
Radcliffe CVRM
Secondary outcomes from the SURMOUNT-OSA trial programme show that tirzepatide significantly improves multiple cardiometabolic risk factors in people with moderate-to-severe obstructive sleep apnoea (OSA) and obesity.¹ The findings suggest that the benefits are mediated through improvements in both body weight and OSA severity metrics.Tirzepatide is a dual glucose-dependent insulinotropic…
View more
Obesity Week 2024
Start date:
Nov 03, 2024
End date:
Nov 06, 2024
Event
Added:
1 year ago
HFSA 2024 - We are joined by Dr Ambarish Pandey (University of Texas Southwestern Medical Center, US) to discuss the findings from HuMAIN HFpEF, a phase 2A randomized, parallel-group, placebo-controlled study of HU6 in patients with obesity and heart failure with preserved ejection fraction (HFpEF).Interview Questions:What is the reasoning behind this study?Could you tell us about the mechanism…
View more
Added:
7 months ago
Source:
Radcliffe CVRM
A new genetic analysis of the SURMOUNT-1 trial data suggests that tirzepatide is an effective treatment for individuals with obesity caused by melanocortin 4 receptor (MC4R) deficiency, the most common monogenic form of the disease.¹ This finding is significant for a patient group in whom lifestyle interventions have previously shown limited success.Tirzepatide is a dual glucose-dependent…
View more
Start date:
May 11, 2025
End date:
May 14, 2025
Event Dates: May 11–14, 2025Location: Malaga, SpainFocus: Obesity research, treatment, and preventionThe European Congress on Obesity (ECO) 2025 is a leading event for healthcare professionals dedicated to addressing obesity through science, policy, and clinical practice. Held in the vibrant city of Malaga, Spain, this congress brings together global experts to share innovative strategies and…
View more
Start date:
Jun 11, 2025